Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RLYB Stock Forecast 2025-2026
$0.33
Current Price
$14.65M
Market Cap
Buy 1
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to RLYB Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
RLYB Price Momentum
+3.1%
1 Week Change
-5.7%
1 Month Change
-77.1%
1 Year Change
-65.6%
Year-to-Date Change
-79.6%
From 52W High of $1.60
+48.2%
From 52W Low of $0.22
📊 TOP ANALYST CALLS
Did RLYB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Rallybio is one of their latest high-conviction picks.
Latest RLYB Stock Price Targets & Analyst Predictions
RLYB has shown a year-to-date change of -65.6% and a 1-year change of -77.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for RLYB. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RLYB Analyst Ratings
1
Buy
3
Hold
0
Sell
RLYB Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.33
Latest RLYB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RLYB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2025 | Jones Trading | Catherine Novack | Hold | Downgrade | $0.00 |
| Apr 9, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Downgrade | $0.00 |
| Mar 17, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $5.00 |
| Feb 12, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $5.00 |
| Jan 13, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $5.00 |
| Dec 3, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $5.00 |
| Nov 22, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $5.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $5.00 |
| Oct 30, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $6.00 |
| Oct 1, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $6.00 |
| Sep 3, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $6.00 |
| Aug 26, 2024 | Evercore ISI Group | Josh Schimmer | Outperform | Maintains | $15.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $6.00 |
| May 15, 2024 | JP Morgan | Anupam Rama | Neutral | Downgrade | $0.00 |
| May 10, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $9.00 |
| Apr 19, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $8.00 |
| Apr 18, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $8.00 |
| Apr 11, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $11.00 |
| Mar 13, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $8.00 |
| Mar 13, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $9.00 |
Rallybio Corporation (RLYB) Competitors
The following stocks are similar to Rallybio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Rallybio Corporation (RLYB) Financial Data
Rallybio Corporation has a market capitalization of $14.65M with a P/E ratio of 0.0x. The company generates $848,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +457.9% quarter-over-quarter, while maintaining an operating margin of -4,561.3% and return on equity of -67.3%.
Valuation Metrics
Market Cap
$14.65M
Enterprise Value
$-39,730,884
P/E Ratio
0.0x
PEG Ratio
-0.3x
Price/Sales
17.3x
Growth & Margins
Revenue Growth (YoY)
+457.9%
Gross Margin
N/A
Operating Margin
-4,561.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+401.8%
Current Ratio
14.7x
Debt/Equity
0.2x
ROE
-67.3%
ROA
-40.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Rallybio Corporation (RLYB) Business Model
About Rallybio Corporation
What They Do
Develops therapies for severe and rare diseases.
Business Model
The company focuses on research and commercialization of biopharmaceuticals aimed at treating life-threatening conditions with unmet medical needs. Rallybio generates revenue through the development of innovative therapies and strategic partnerships with research institutions, leveraging scientific advancements to expedite drug development.
Additional Information
Rallybio operates within the biotechnology and healthcare sectors, particularly addressing genetic disorders and immunological diseases. Its collaborations and commitment to scientific excellence play a crucial role in improving patient outcomes and advancing medical science, positioning the company as a significant player in the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
24
CEO
Dr. Stephen Uden M.B, M.D.
Country
United States
IPO Year
2021
Website
www.rallybio.comRallybio Corporation (RLYB) Latest News & Analysis
Latest News
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
7 days ago
Quick Summary
Rallybio Corporation (Nasdaq: RLYB) has begun dosing in a Phase 1 PK/PD study for RLYB116, a once-weekly subcutaneous C5 inhibitor aimed at treating rare diseases.
Why It Matters
Rallybio's Phase 1 study for RLYB116 may signal progress in rare disease therapies, potentially impacting stock performance and market confidence in its innovative pipeline.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Rallybio Corporation (Nasdaq: RLYB) reported Q1 financial results for the period ending March 31, 2025, and plans to advance RLYB116 into a confirmatory study this quarter.
Why It Matters
Rallybio's advancement of RLYB116 into a confirmatory study suggests progress in drug development, potentially enhancing its value and attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Rallybio Corporation's CEO, Dr. Stephen Uden, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on May 7, 2025, at 12:00 p.m. ET. A live webcast will be available.
Why It Matters
Rallybio's CEO participation in a prominent conference indicates potential for visibility and investor interest in its innovative therapies, impacting stock performance and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Rallybio has halted development of RLYB212 in a phase II study for fetal and neonatal alloimmune thrombocytopenia, resulting in a decline in stock price.
Why It Matters
Rallybio's halted RLYB212 development signals potential setbacks in drug pipeline, impacting future revenue and investor confidence, leading to a stock decline.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Rallybio Corporation (RLYB) has discontinued its RLYB212 program aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Why It Matters
Discontinuing the RLYB212 program may signal potential setbacks in product pipeline and revenue, affecting RLYB's stock performance and investor confidence.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Rallybio Corporation (Nasdaq: RLYB) has discontinued the RLYB212 program for preventing fetal and neonatal alloimmune thrombocytopenia due to unfavorable Phase 2 trial pharmacokinetic data.
Why It Matters
The discontinuation of the RLYB212 program signals potential setbacks for Rallybio, impacting its future revenue prospects and investor confidence in its pipeline.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About RLYB Stock
What is Rallybio Corporation's (RLYB) stock forecast for 2025?
Analyst forecasts for Rallybio Corporation (RLYB) are not currently available. The stock is trading at $0.33.
Is RLYB stock a good investment in 2025?
According to current analyst ratings, RLYB has 1 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.33. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RLYB stock?
Price predictions from Wall Street analysts for RLYB are not currently available. The stock is trading at $0.33.
What is Rallybio Corporation's business model?
The company focuses on research and commercialization of biopharmaceuticals aimed at treating life-threatening conditions with unmet medical needs. Rallybio generates revenue through the development of innovative therapies and strategic partnerships with research institutions, leveraging scientific advancements to expedite drug development.
What is the highest forecasted price for RLYB Rallybio Corporation?
Price targets from Wall Street analysts for RLYB are not currently available. The stock is trading at $0.33.
What is the lowest forecasted price for RLYB Rallybio Corporation?
Price targets from Wall Street analysts for RLYB are not currently available. The stock is trading at $0.33.
What is the overall RLYB consensus from analysts for Rallybio Corporation?
The overall analyst consensus for RLYB is neutral. Out of 8 Wall Street analysts, 1 rate it as Buy, 3 as Hold, and 0 as Sell.
How accurate are RLYB stock price projections?
Stock price projections, including those for Rallybio Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 10:53 AM UTC